

Safety Data Sheet

According to Canadian Hazardous Products Regulations and WHMIS 2015

Initial preparation date: 2023.12.08

Page 1 of 12

Equipalazone (Oral powder)

SECTION 1: Identification

Product identifier

Product name: Equipalazone (Oral powder)

Synonyms: Phenylbutazone

Recommended use of the product and restriction on use

Relevant identified uses: VETERINARY USE: For the treatment of musculoskeletal disorders in horses and ponies.

Uses advised against: Not for human use.

Reasons why uses advised against: Not determined or not applicable.

Manufacturer or supplier details

Supplier:

Canada

Dechra Veterinary Products
1 Holiday Ave. East Tower
Suite 345
Point Claire, QC H9R 5N3
855-332-9334

Emergency telephone number:

Canada

Dechra Veterinary Products
855-332-9334 (Normal Business hours)

SECTION 2: Hazard identification

GHS classification:

Acute toxicity (oral), category 4

Acute toxicity (dermal), category 4

Acute toxicity (inhalation), category 4

Skin irritation, category 2

Eye irritation, category 2A

Respiratory sensitization, category 1

Skin sensitization, category 1

Carcinogenicity, category 2

Reproductive toxicity, category 2

Specific target organ toxicity - single exposure, category 3, respiratory tract irritation

Label elements

Hazard pictograms:



Safety Data Sheet

According to Canadian Hazardous Products Regulations and WHMIS 2015

Initial preparation date: 2023.12.08

Page 2 of 12

Equipalazone (Oral powder)

Signal Word: Danger

Hazard statements:

- H315 Causes skin irritation
- H319 Causes serious eye irritation
- H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled
- H317 May cause an allergic skin reaction
- H351 Suspected of causing cancer if inhaled.
- H361 Suspected of damaging fertility or the unborn child.
- H335 May cause respiratory irritation
- H332 Harmful if inhaled
- H312 Harmful in contact with skin
- H302 Harmful if swallowed

Precautionary statements:

- P201 Obtain special instructions before use
- P202 Do not handle until all safety precautions have been read and understood
- P280 Wear protective gloves, protective clothing, eye protection and face protection.
- P271 Use only outdoors or in a well-ventilated area
- P261 Avoid breathing dust.
- P284 In case of inadequate ventilation wear respiratory protection.
- P270 Do not eat, drink or smoke when using this product
- P272 Contaminated work clothing should not be allowed out of the workplace
- P264 Wash hands thoroughly for 15 minutes after handling.
- P302+P352 IF ON SKIN: Wash with plenty of water and soap.
- P361+P364 Take off immediately all contaminated clothing and wash it before reuse
- P321 Specific treatment (see Sections 4-8 of this SDS and any supplemental information on the product label).
- P333+P313 If skin irritation or rash occurs: Get medical attention.
- P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing
- P337+P313 If eye irritation persists: Get medical attention.
- P304+P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing
- P342+P311 If experiencing respiratory symptoms: Call a doctor.
- P301+P312 IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell
- P330 Rinse mouth
- P312 Call a POISON CENTER/doctor if you feel unwell
- P308+P313 If exposed or concerned: Get medical advice.
- P405 Store locked up
- P403+P233 Store in a well-ventilated place. Keep container tightly closed
- P501 Dispose of contents and container in accordance with local regulations.

Hazards not otherwise classified:

None

Supplemental label elements:

- 0 percent of the mixture consists of ingredient(s) of unknown acute oral toxicity
- 0 percent of the mixture consists of ingredient(s) of unknown acute dermal toxicity
- 0 percent of the mixture consists of ingredient(s) of unknown acute inhalation toxicity

Safety Data Sheet

According to Canadian Hazardous Products Regulations and WHMIS 2015

Initial preparation date: 2023.12.08

Page 3 of 12

Equipalazone (Oral powder)

SECTION 3: Composition/information on ingredients

Identification	Name	Weight %
CAS number: 50-33-9	Phenylbutazone	>55
CAS number: 9000-70-8	Gelatin	10-20
CAS number: 9000-01-5	Gum arabic	10-20
CAS number: 7631-86-9	Silicon dioxide (amorphous)	1-10

Additional Information:

The specific chemical identity and/or exact percentage (concentration) of composition has been withheld as a trade secret in accordance with the Canadian Hazardous Products Regulation and WHMIS 2015.

SECTION 4: First-aid measures

Description of first-aid

measures General notes:

Show this Safety Data Sheet to the doctor in attendance. Take precautions to ensure your own safety before attempting rescue. Wear appropriate safety eyewear, gloves, protective clothing and respiratory protection to prevent exposure. See Section 8 of this SDS for personal protective equipment recommendations. Do not use the mouth to mouth method if victim has ingested or inhaled the product. Give artificial respiration with the aid of a pocket mask equipped with a one-way valve or other proper device.

After inhalation:

If inhaled, remove person to fresh air and place in a position comfortable for breathing. Keep person at rest. If breathing is difficult, administer oxygen. If breathing has stopped, provide artificial respiration. If experiencing respiratory symptoms, seek medical advice/attention.

After skin contact:

Remove contaminated clothing and shoes. Rinse skin with copious amounts of water [shower] for several minutes. Launder contaminated clothing before reuse. If symptoms develop or persist, seek medical advice/attention.

After eye contact:

Rinse eyes with plenty of gently flowing lukewarm water for 15 minutes. Remove contact lenses if present and easy to do so. Protect unexposed eye. If symptoms develop or persist, seek medical advice/attention.

After ingestion:

If swallowed, DO NOT induce vomiting unless told to do so by a physician or poison control center. Rinse mouth with water. Never give anything by mouth to an unconscious person. If spontaneous vomiting occurs, place on the left side with head down to prevent aspiration of liquid into the lungs. If symptoms develop or persist, seek medical advice/attention.

Most important symptoms and effects, both acute and delayed

Acute symptoms and effects:

Acute oral exposure may lead to dizziness, drowsiness, headache, breathing difficulties, nausea, vomiting, abdominal pain, and lowering of consciousness. Adverse effects are dependent on exposure (dose, concentration, contact time).

Eye contact may result in irritation, redness, pain, inflammation, itching, burning and tearing.

Safety Data Sheet

According to Canadian Hazardous Products Regulations and WHMIS 2015

Initial preparation date: 2023.12.08

Page 4 of 12

Equipalazone (Oral powder)

Inhalation exposure may cause allergy, asthma symptoms or breathing difficulties. Symptoms may include cough, chronic phlegm, shortness of breath, wheezing and chest tightness. Symptoms may be delayed.

Acute inhalation exposure may lead to dizziness, drowsiness, headache, breathing difficulties, nausea, vomiting, abdominal pain, and lowering of consciousness. Adverse effects are dependent on exposure (dose, concentration, contact time).

Dermal exposure may cause an allergic skin reaction. Symptoms may include irritation, redness, pain, rash, inflammation, itching, burning and dermatitis.

Acute dermal exposure may lead to dizziness, drowsiness, headache, breathing difficulties, nausea, vomiting, abdominal pain, and lowering of consciousness. Adverse effects are dependent on exposure (dose, concentration, contact time).

Delayed symptoms and effects:

Suspected of causing cancer. Effects are dependent on exposure (dose, concentration, contact time). Long term exposure may affect fertility. Symptoms include, but are not limited to: menstrual problems, altered sexual behavior/fertility/ and pregnancy outcome. Long term exposure may also affect development of the unborn child. Symptoms include, but are not limited to: intrauterine growth retardation, pre-term birth, birth defects and postnatal death. Symptoms of exposure may be delayed.

Immediate medical attention and special treatment

Specific treatment:

If respiratory symptoms persist, seek medical attention.

Notes for the doctor:

Treat symptomatically.

SECTION 5: Fire-fighting measures

Extinguishing media

Suitable extinguishing media:

Water mist/fog, carbon dioxide, dry chemical or alcohol resistant foam.

Unsuitable extinguishing media:

Do not use water jet.

Specific hazards during fire-fighting:

Thermal decomposition may produce irritating/toxic fumes/gases.

Special protective equipment for firefighters:

Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full-face piece operated in positive pressure mode.

Special precautions:

Avoid contact with skin, eyes, hair and clothing. Do not breathe fumes/gas/mists/aerosols/vapors/dusts. Move containers from fire area if safe to do so. Use water spray/fog for cooling fire exposed containers. Avoid unnecessary run-off of extinguishing media which may cause pollution.

SECTION 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures:

Evacuate unnecessary personnel. Ventilate area. Extinguish any sources of ignition. Wear recommended personal protective equipment (see Section 8). Do not get on skin, eyes or on clothing. Avoid breathing mist, vapor, dust, fume and spray. Do not walk through spilled material. Wash thoroughly after handling. Remove contaminated clothing and laundry before reuse.

Safety Data Sheet

According to Canadian Hazardous Products Regulations and WHMIS 2015

Initial preparation date: 2023.12.08

Page 5 of 12

Equipalazone (Oral powder)

Environmental precautions:

Prevent further leakage or spillage if safe to do so. Prevent from reaching drains, sewers and waterways. Discharge into the environment must be avoided.

Methods and material for containment and cleaning up:

Harmful in contact with skin, if inhaled or if swallowed. Put on appropriate personal protective equipment, including a self-contained breathing apparatus (see Section 8) before entering area of spill or leak. Avoid breathing dust, mist, fumes, vapors or spray. Do not touch damaged containers or spilled material unless wearing appropriate personal protective clothing. Stop leak if you can do it without risk. Contain and collect spillage and place in suitable container for future disposal. Dispose of in accordance with all applicable regulations (see Section 13).

Reference to other sections:

For personal protective equipment see Section 8. For disposal see Section 13.

SECTION 7: Handling and storage

Precautions for safe handling:

Use appropriate personal protective equipment (see Section 8). Use only with adequate ventilation. Avoid breathing mist/vapor/spray/dust. Do not eat, drink, smoke, or use personal products when handling chemical substances. Avoid contact with skin, eyes and clothing. Wash affected areas thoroughly after handling. Keep away from incompatible materials (See Section 10). Keep containers tightly closed when not in use.

Conditions for safe storage, including any incompatibilities:

Do not store above 25°C. Store in a dry place.

SECTION 8: Exposure controls/personal protection



Only those substances with limit values have been included below.

Occupational Exposure limit values:

Country (Legal Basis)	Substance	Identifier	Permissible concentration
British Columbia	Silicon dioxide (amorphous)	7631-86-9	8-Hour TWA: 4 mg/m ³ (precipitated and gel, total)
	Silicon dioxide (amorphous)	7631-86-9	8-Hour TWA: 1.5 mg/m ³ (precipitated and gel, respirable)
Quebec	Silicon dioxide (amorphous)	7631-86-9	8-Hour TWA: 6 mg/m ³ (respirable dust)
Ontario	Silicon dioxide (amorphous)	7631-86-9	8-Hour TWA: 10 mg/m ³ (PNOS, inhalable particles)
	Silicon dioxide (amorphous)	7631-86-9	8-Hour TWA: 3 mg/m ³ (respirable particles)
New Brunswick	Silicon dioxide (amorphous)	7631-86-9	8-Hour TWA: 3 mg/m ³ (respirable particles)
	Silicon dioxide (amorphous)	7631-86-9	8-Hour TWA: 10 mg/m ³ (inhalable particles)

Safety Data Sheet

According to Canadian Hazardous Products Regulations and WHMIS 2015

Initial preparation date: 2023.12.08

Page 6 of 12

Equipalazone (Oral powder)

Country (Legal Basis)	Substance	Identifier	Permissible concentration
Saskatchewan	Silicon dioxide (amorphous)	7631-86-9	8-Hour TWA: 10 mg/m ³ (inhalable fraction)
	Silicon dioxide (amorphous)	7631-86-9	15-Minute STEL: 20 mg/m ³ (inhalable fraction)
	Silicon dioxide (amorphous)	7631-86-9	8-Hour TWA: 3 mg/m ³ (respirable fraction)
	Silicon dioxide (amorphous)	7631-86-9	15-Minute STEL: 6 mg/m ³ (respirable fraction)
Alberta	Silicon dioxide (amorphous)	7631-86-9	8-Hour TWA: 3 mg/m ³ (respirable fraction)
	Silicon dioxide (amorphous)	7631-86-9	8-Hour TWA: 10 mg/m ³ (PNOS, total dust)
Manitoba	Silicon dioxide (amorphous)	7631-86-9	8-Hour TWA: 10 mg/m ³ (inhalable fraction)
	Silicon dioxide (amorphous)	7631-86-9	8-Hour TWA: 3 mg/m ³ (respirable fraction)

Biological limit values:

No biological exposure limits noted for the ingredient(s).

Information on monitoring procedures:

Not determined or not applicable.

Appropriate engineering controls:

Emergency eye wash stations and safety showers should be available in the immediate vicinity of use or handling. Provide adequate ventilation to maintain the airborne concentrations of vapor, mists, and/or dusts below the applicable workplace exposure limits, while observing recognized national standards (or equivalent).

Personal protection equipment

Eye and face protection:

Safety glasses or goggles. Use eye protection equipment that has been tested and approved by recognized national standards (or equivalent).

Skin and body protection:

Chemical resistant, impervious gloves approved by the appropriate standards. Gloves must be inspected prior to use. Avoid skin contact with used gloves. Appropriate techniques should be used to remove used gloves and contaminated clothing. Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. Ensure that all personal protective equipment is approved by recognized national standards (or equivalent).

Respiratory protection:

If engineering controls do not maintain airborne concentrations below the applicable workplace exposure limits, or to an acceptable level (if exposure limits have not been established), a respirator approved by recognized national standards (or equivalent) must be worn. Use a positive pressure air supplied respirator if there is any potential for an uncontrolled release, exposure levels are not known, or any other circumstances where air purifying respirators may not provide adequate protection.

General hygienic measures:

When handling chemical products, do not eat, drink or smoke. Wash hands after handling, before breaks, and at the end of the workday. Avoid contact with skin, eyes and clothing. Wash contaminated clothing before reuse. Perform routine housekeeping.

Safety Data Sheet

According to Canadian Hazardous Products Regulations and WHMIS 2015

Initial preparation date: 2023.12.08

Page 7 of 12

Equipalazone (Oral powder)

SECTION 9: Physical and chemical properties

Information on basic physical and chemical properties

Appearance (physical state, color):	White or almost white, crystalline powder
Odor:	Apple
Odor threshold:	Not determined or not available.
pH-value:	Not determined or not available.
Melting/Freezing point:	106-108°C / 222 - 226.4°F
Boiling point/range:	Not determined or not available.
Flash point:	Not determined or not available.
Evaporation rate:	Not determined or not available.
Flammability (solid, gaseous):	Non-flammable
Explosion limit upper:	Not determined or not available.
Explosion limit lower:	Not determined or not available.
Vapor pressure:	Not determined or not available.
Vapor density:	Not determined or not available.
Density:	Not determined or not available.
Relative density:	Not determined or not available.
Solubilities:	Soluble in water. Water solubility 0.7 g/L
Partition coefficient (n-)	Not determined or not available.
Auto/Self-ignition temperature:	440°C / 824°F
Decomposition temperature:	Not determined or not available.
Dynamic viscosity:	Not determined or not available.
Kinematic viscosity:	Not determined or not available.
Explosive properties	Not determined or not available.
Oxidizing properties	Not determined or not available.

SECTION 10: Stability and reactivity

Reactivity:

Not reactive under recommended handling and storage conditions.

Chemical stability:

Stable under recommended handling and storage conditions.

Possibility of hazardous reactions:

Hazardous reactions are not anticipated under recommended conditions of handling and storage.

Conditions to avoid:

Avoid confined spaces, extreme heat, open flames, hot surfaces, sparks, ignition sources and incompatible materials.

Incompatible materials:

None known.

Hazardous decomposition products:

Under normal conditions of storage and use, hazardous decomposition products should not be produced.

Safety Data Sheet

According to Canadian Hazardous Products Regulations and WHMIS 2015

Initial preparation date: 2023.12.08

Page 8 of 12

Equipalazone (Oral powder)

SECTION 11: Toxicological information

Acute toxicity

Assessment:

Harmful if inhaled.
Harmful in contact with skin.
Harmful if swallowed.

Product data: No data available.

Substance data:

Name	Route	Result
Phenylbutazone	oral	LD50 Rat: 245 mg/kg
	Dermal ATE	LD50 Rabbit: 1100 mg/kg
	Inhalation ATE	LC50 Rat: 1.5 mg/L (4 hr [dust/mist])
Silicon dioxide (amorphous)	oral	LD50 Rat: > 5000 mg/kg
	dermal	LD50 Rat: > 2000 mg/kg
	inhalation	LC50 Rat: > 5.01 mg/L (4hr [Aerosol])
Gum arabic	oral	LD50 Rat: 16,000 mg/kg

Skin corrosion/irritation

Assessment:

Causes skin irritation.

Product data:

No data available.

Substance data:

Name	Result
Phenylbutazone	Causes skin irritation.

Serious eye damage/irritation

Assessment:

Causes serious eye irritation.

Product data:

No data available.

Substance data:

Name	Result
Phenylbutazone	Causes serious eye irritation.

Respiratory or skin sensitization

Assessment:

May cause allergy or asthma symptoms or breathing difficulties if inhaled.
May cause an allergic skin reaction.

Product data:

No data available.

Substance data:

Name	Result
Phenylbutazone	May cause an allergic skin reaction.
	May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Safety Data Sheet

According to Canadian Hazardous Products Regulations and WHMIS 2015

Initial preparation date: 2023.12.08

Page 9 of 12

Equipalazone (Oral powder)

Name	Result
Gum arabic	Some studies have found exposure to airborne particles of this substance to cause an allergic sensitivity characterized by occupational catarrhal inflammation and asthma, as well as irritation of nasal mucous, sinus, throat, respiratory tract, and bronchus in some individuals. However, this is not sufficient to cause classification of the substance as a Respiratory Sensitizer.

Carcinogenicity

Assessment:

Suspected of causing cancer.

Product data: No data available.

Substance data: No data available.

International Agency for Research on Cancer (IARC):

Name	Classification
Phenylbutazone	Group 3
Silicon dioxide (amorphous)	Group 3

National Toxicology Program (NTP): None of the ingredients are listed.

Germ cell mutagenicity

Assessment: Based on available data, the classification criteria are not met.

Product data:

No data available.

Substance data: No data available.

Reproductive toxicity

Assessment:

Suspected of damaging fertility or the unborn child.

Product data:

No data available.

Substance data:

Name	Result
Phenylbutazone	Suspected of damaging fertility or the unborn child.

Specific target organ toxicity (single exposure)

Assessment:

May cause respiratory irritation.

Product data:

No data available.

Substance data:

Name	Result
Phenylbutazone	May cause respiratory irritation.

Specific target organ toxicity (repeated exposure)

Assessment: Based on available data, the classification criteria are not met.

Product data:

No data available.

Substance data: No data available.

Safety Data Sheet

According to Canadian Hazardous Products Regulations and WHMIS 2015

Initial preparation date: 2023.12.08

Page 10 of 12

Equipalazone (Oral powder)

Aspiration toxicity

Assessment: Based on available data, the classification criteria are not met.

Product data:

No data available.

Substance data: No data available.

Information on likely routes of exposure:

Inhalation, oral ingestion, skin and eye contact.

Symptoms related to the physical, chemical and toxicological characteristics:

See section 4 of this SDS.

Other information:

No data available.

SECTION 12: Ecological information

Acute (short-term) toxicity

Assessment: Based on available data, the classification criteria are not met.

Product data: No data available.

Substance data:

Name	Result
Silicon dioxide (amorphous)	Fish LC50 Pimephales promelas: >5000 mg/L (96 hr)
	Aquatic Invertebrates EC50 Daphnia magna: >5000 mg/L (48 hr [mobility])
	Aquatic Plants EC50 Desmodemus subspicatus: >173.1 mg/L (72 hr [growth rate])

Chronic (long-term) toxicity

Assessment: Based on available data, the classification criteria are not met.

Product data: No data available.

Substance data:

Name	Result
Silicon dioxide (amorphous)	Aquatic Invertebrates NOEC Daphnia magna: 68 mg/L (21 d [morality])

Persistence and degradability

Product data: No data available.

Substance data:

Name	Result
Silicon dioxide (amorphous)	The substance is inorganic hence study does not need to be conducted.

Bioaccumulative potential

Product data: No data available.

Substance data:

Name	Result
Gelatin	This substance is a hydrocarbon UVCB. Standard tests for this endpoint are intended for single substances and are not appropriate for this complex substance.
Silicon dioxide (amorphous)	The substance is inorganic hence study does not need to be conducted.

Safety Data Sheet

According to Canadian Hazardous Products Regulations and WHMIS 2015

Initial preparation date: 2023.12.08

Page 11 of 12

Equipalazone (Oral powder)

Mobility in soil

Product data: No data available.

Substance data:

Name	Result
Gelatin	This substance is a hydrocarbon UVCB. Standard tests for this endpoint are intended for single substances and are not appropriate for this complex substance.

Results of PBT and vPvB assessment

Product data:

PBT assessment: This product does not contain any substances that are assessed to be a PBT.

vPvB assessment: This product does not contain any substances that are assessed to be a vPvB.

Substance data:

PBT

assessment:

Silicon dioxide (amorphous)	The substance is not PBT.
-----------------------------	---------------------------

vPvB assessment:

Silicon dioxide (amorphous)	The substance is not vPvB.
-----------------------------	----------------------------

Other adverse effects: No data available.

SECTION 13: Disposal considerations

Disposal methods:

It is the responsibility of the waste generator to properly characterize all waste materials according to applicable regulatory entities

Contaminated packages:

Not determined or not applicable.

SECTION 14: Transport information

Canadian Transportation of Dangerous Goods (TDG)

UN number	Not regulated
UN proper shipping name	Not regulated
UN transport hazard class(es)	None
Packing group	None
Environmental hazards	None
Special precautions for user	None

International Maritime Dangerous Goods (IMDG)

UN number	Not regulated
UN proper shipping name	Not regulated
UN transport hazard class(es)	None
Packing group	None
Environmental hazards	None
Special precautions for user	None

Safety Data Sheet

According to Canadian Hazardous Products Regulations and WHMIS 2015

Initial preparation date: 2023.12.08

Page 12 of 12

Equipalazone (Oral powder)

International Air Transport Association Dangerous Goods Regulations (IATA-DGR)

UN number	Not regulated
UN proper shipping name	Not regulated
UN transport hazard class(es)	None
Packing group	None
Environmental hazards	None
Special precautions for user	None

Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code

Bulk Name	None
Ship type	None
Pollution category	None

SECTION 15: Regulatory information

Canada regulations

Domestic substances list (DSL): All ingredients are listed or exempt.

Non-domestic substances list (NDSL): None of the ingredients are listed.

Additional information: Not determined.

SECTION 16: Other information

Abbreviations and Acronyms: None

Disclaimer:

This product has been classified in accordance with the Canadian Hazardous Products Regulations and WHMIS 2015. The information provided in this SDS is correct, to the best of our knowledge, based on information available. The information given is designed only as a guidance for safe handling, use, storage, transportation and disposal and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials, unless specified in the text. The responsibility to provide a safe workplace remains with the user.

Initial preparation date: 2023.12.08

Revision notes:

Revision Date	Notes
2023-12-08	Version 1

End of Safety Data Sheet